Morningstar

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...
Medscape

New Dexcom G7 Feature Cleared as 15-day Sensor Set to Launch

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Nasdaq

Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Morningstar

Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...
Hosted on MSN

"It’s life-threatening"—Dexcom G7 users say glucose monitor is failing them

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...